Wilson Therapeutics Explained

Wilson Therapeutics AB
Type:Public company
Traded As:OMX: WTX
Industry:Pharmaceutical industry
Products:Decuprate
Parent:Alexion Pharmaceuticals
Homepage:www.wilsontherapeutics.com
Foundation:2012
Location City:Stockholm
Location Country:Sweden

Wilson Therapeutics is a biopharmaceutical company, based in Stockholm, Sweden, that develops novel therapies for rare diseases. The company is listed in the Mid-Cap segment on Nasdaq Stockholm with the stock ticker WTX.

Wilson Therapeutics' lead product, Decuprate, is the proprietary bis-choline salt of tetrathiomolybdate. Decuprate is initially being developed as a novel treatment for Wilson's disease, a rare genetic disease that affects approximately 1 in 30,000, causing copper overload in the liver, brain and other tissues and resulting in organ damage and dysfunction.[1] Decuprate has been granted orphan drug designation for the treatment of Wilson's disease in both Europe and the United States.[2] Wilson Therapeutics presented during the 10th Kempen & Co Life Sciences Conference 2017 and showed the world the result with the drug Decuprate. The company also presented during the international investmentconference Bioequity Europe in Paris, France, on May 23, 2017, and showed some promising result.

Clinical trials

As of 2016, tetrathiomolybdate had been tested in over 500 patients for up to seven years, primarily in oncology[3] [4] [5] [6] [7] [8] [9] [10] [11] [12] and Wilson's disease,[13] [14] [15] [16] as well as some other clinical pathologies.[17] [18]

History

Wilson Therapeutics was founded in 2012 by HealthCap, one of the leading European life science venture capital funds.[19] In 2014, Wilson Therapeutics closed a $40 million Series B financing co-led by new investors, Abingworth LLP, MVM Life Science Partners LLP and NeoMed Management AS. HealthCap also participated in the round.[20] [21] On April 29, 2016, Wilson Therapeutics announced its initial public offering on Nasdaq Stockholm and had its first day of trading on May 12, 2016.[22] [23]

Notes and References

  1. Ala A, Walker AP, Ashkan K, Dooley JS, Schilsky ML. 2007. "Wilson's disease." Lancet 369:397-408.
  2. http://www.accessdata.fda.gov/scripts/opdlisting/oopd/OOPD_Results_2.cfm?Index_Number=346511 U.S. Food and Drug Administration Orphan Drug Designations and Approvals
  3. Berenson JR, Boccia RV, Bashey A, Levine AM, Koc ON, Callahan JA, Mazar AP, Reich SD, 2006. "Phase I Study of the [Cu, Zn] Superoxide Dismutase (SOD1) Inhibitor ATN-224 (Bis-Choline Tetrathiomolybdate) in Patients with Advanced Hematologic Malignancies. Presentation at the Amer Soc Hematol 2006 Annual Meeting". Blood 108: Abstract 2593.
  4. Brewer GJ, Dick RD, Grover DK, LeClaire V, Tseng M, Wicha M, Pienta K, Redman BG, Jahan T, Sondak VK, Strawderman M, LeCarpentier G, Merajver SD, 2000. "Treatment of metastatic cancer with tetrathiomolybdate, an anticopper, antiangiogenic agent: Phase I study". Clin Cancer Res 6: 1-10.
  5. Gartner EM, Griffith KA, Pan Q, Brewer GJ, Henja GF, Merajver SD, Zalupski MM, 2009. "A pilot trial of the anti-angiogenic copper lowering agent tetrathiomolybdate in combination with irinotecan, 5-flurouracil, and leucovorin for metastatic colorectal cancer". Invest New Drugs 27: 159-165.
  6. Henry NL, Dunn R, Merjaver S, Pan Q, Pienta KJ, Brewer G, Smith DC, 2006. "Phase II trial of copper depletion with tetrathiomolybdate as an antiangiogenesis strategy in patients with hormone-refractory prostate cancer". Oncology 71: 168-175.
  7. Jain S, Cohen J, Ward MM, Kornhauser N, Chuang E, Cigler T, Moore A, Donovan D, Lam C, Cobham MV, Schneider S, Hurtado Rua SM, Benkert S, Mathijsen Greenwood C, Zelkowitz R, Warren JD, Lane ME, Mittal V, Rafii S, Vahdat LT, 2013. "Tetrathiomolybdate-associated copper depletion decreases circulating endothelial progenitor cells in women with breast cancer at high risk of relapse". Annals of Oncology.
  8. Lin J, Zahurak M, Beer TM, Ryan CJ, Wilding G, Mathew P, Morris M, Callahan JA, Gordon G, Reich SD, Carducci MA, Antonarakis ES, 2011. "A non-comparative randomized phase II study of 2 doses of ATN-224, a copper/zinc superoxide dismutase inhibitor, in patients with biochemically recurrent hormone-naive prostate cancer". Urologic oncology. 31(5):581-8.
  9. Lowndes SA, Adams A, Timms A, Fisher N, Smythe J, Watt SM, Joel S, Donate F, Hayward C, Reich S, Middleton M, Mazar A, Harris AL, 2008. "Phase I study of copper-binding agent ATN-224 in patients with advanced solid tumors". Clin Cancer Res 14: 7526-7534.
  10. Pass HI, Brewer GJ, Dick R, Carbone M, Merajver S, 2008. "A phase II trial of tetrathiomolybdate after surgery for malignant mesothelioma: final results". Ann Thorac Surg 86: 383-389; discussion 390.
  11. Redman BG, Esper P, Pan Q, Dunn RL, Hussain HK, Chenevert T, Brewer GJ, Merajver SD, 2003. "Phase II trial of tetrathiomolybdate in patients with advanced kidney cancer". Clin Cancer Res 9: 1666-1672.
  12. Schneider BJ, Lee JS, Hayman JA, Chang AC, Orringer MB, Pickens A, Pan CC, Merajver SD, Urba SG, 2012. "Pre-operative chemoradiation followed by post-operative adjuvant therapy with tetrathiomolybdate, a novel copper chelator, for patients with resectable esophageal cancer". Invest New Drugs.
  13. Roberts EA, Schilsky L, 2008. "Diagnosis and Treatment of Wilson Disease: An Update." "AASDL Clinical Practice Guidelines in Wilson Disease." Hepatology 47,6:2089-2111.
  14. Brewer GJ, Askari F, Dick RB, Sitterly J, Fink JK, Carlson M, Kluin KJ, Lorincz MT, 2009. "Treatment of Wilson's disease with tetrathiomolybdate: V. Control of free copper by tetrathiomolybdate and a comparison with trientine". Translational Research 154: 70-77.
  15. Brewer GJ, Askari F, Lorincz, MT, Carlson M, Schilsky M, Kluin KJ, Hedera P, Moretti P, Fink JK, Tankanow R, Dick RB, Sitterly J, 2006. "Treatment of Wilson disease with ammonium tetrathiomolybdate: IV. Comparison of tetrathiomolybdate and trientine in a double-blind study of treatment of the neurologic presentation of Wilson disease". Arch Neurol 63: 521-527.
  16. Brewer GJ, Hedera P, Kluin KJ, Carlson M, Askari F, Dick RB, Sitterly J, Fink JK, 2003. "Treatment of Wilson disease with ammonium tetrathiomolybdate: III. Initial therapy in a total of 55 neurologically affected patients and follow-up with zinc therapy". Arch Neurol 60: 379-385.
  17. Askari F, Innis D, Dick RB, Hou G, Marrero J, Greenson J, Brewer GJ, 2010. "Treatment of primary biliary cirrhosis with tetrathiomolybdate: results of a double-blind trial." Translational Research 155: 123-130.
  18. Vine AK, Brewer GJ, 2002. "Tetrathiomolybdate as an antiangiogenesis therapy for subfoveal choroidal neovascularization secondary to age-related macular degeneration". Trans Am Ophthalmol Soc 100: 73-76; discussion 76-77.
  19. "Wilson Therapeutics" Life Science Sweden. April 17, 2014.
  20. "Wilson Therapeutics Raises $40M Series B to Rid Body of Excess Copper." Private Equity and Venture Capital Dow Jones. April 16, 2014.
  21. "Venture Capitalists support new approach to pain." MedNous Opportunities in European Medical Innovation. 8(5):19. May 2014.
  22. Web site: Wilson Therapeutics vill noteras på Stockholmsbörsen. 29 April 2016.
  23. Web site: Unknown.

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Wilson Therapeutics".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.